Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

British Journal of Cancer

Volumn 81, Issue 2, 1999, Pages 242-251

  Culig, Z ^a   Hoffmann, J ^c   Erdel, M ^b   Eder, I E ^a   Hobisch, A ^a   Hittmair, A ^b   Bartsch, G ^a   Utermann, G ^b   Schneider, M R ^c   Parczyk, K ^c   Klocker, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c BAYER PHARMA AG   (Germany)

Author keywords

Androgen ablation; Androgen receptor; Bicalutamide; LNCaP cells; Prostate cancer; Tumour progression

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; COMPLEMENTARY DNA; HYDROXYFLUTAMIDE; METRIBOLONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG MECHANISM; GENE ACTIVITY; GENE AMPLIFICATION; GENE INDUCTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REPORTER GENE; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSACTIVATION; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; HUMANS; LIGANDS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0032883932     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690684     Document Type: Article

References (44)

1. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB and Jensen RH (1996) Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56: 3091-3102
2. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G and Klocker H (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541-1550
3. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV and Bartsch G (1993b) DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22: 11-22
4. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G and Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478
5. Cronauer MV, Klocker H, Talasz H, Geisen FH, Hobisch A, Radmayr C, Böck G, Culig Z, Schirmer M, Reissigl A, Bartsch G and Konwalinka G (1996) Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate 28: 172-181
6. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G and Klocker H (1997a) Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 32: 106-114
7. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Bartsch G and Klocker H (1997b) Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging 10: 50-58
8. Dijkman GA and Debruyne FM (1996) Epidemiology of prostate cancer. Eur Urol 30: 281-298
9. Froesch BA, Takayama S and Reed JC (1998) BAG-1L protein enhances androgen receptor function. J Biol Chem 273: 11660-11666
10. Gibas Z, Becher R, Kawinski E, Horoszewicz J and Sandberg AA (1984) A high-resolution study of chromosome changes in a human prostate carcinoma cell line. Cancer Genet Cytogenet II: 399-404
11. Gupta C, Chandorkar A and Nguyen AP (1996) Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation. Mol Cell Endocrinol 123: 89-95
12. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H and Hittmair A (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55: 3068-3072
13. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H and Hittmair A (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28: 129-135
14. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818
15. Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LWK and Visakorpi T (1997) Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 75: 190-195
16. Ikonen T, Palvimo JJ and Jänne OA (1997) Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates trancriptional activity and is influenced hy nuclear receptor coactivators. J Biol Chem 212: 29821-29828
17. Jeng M-H, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura RJ and Santen RJ (1998) Estrogen receptor expression and function in longterm estrogen-deprived human breast cancer cells. Endocrinology 139: 4164-4174
18. Kaighn ME, Shankar Narayan K, Ohnuki Y, Lechner JF and Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23
19. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW and Pinkel D (1994) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10: 231-243
20. Kirschenbaum A, Ren M and Levine AC (1993) Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line. Steroids 58: 439-444
21. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T and Kallioniemi OP (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319
22. Kokontis J, Takakura K, Hay N and Liao S (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54: 1566-1573
23. Kokontis JM, Hay N and Liao S (1998) Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip 1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953
24. Konig JJ, Kamst E, Hagemeijer A, Romijn JC, Horoszewicz J and Schröder FH (1989) Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP. Urol Res 17: 79-86
25. Langer PR, Waldrop AA, Ward DC (1981) Enzymatic synthesis of biotin-labeled polynucleotides: novel nucleic acid affinity probes. Proc Natl Acad Sci USA 78; 6633-6637
26. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Antsel I, Shaw N, Prins GS and Kozłowski JM (1995) Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136: 796-805
27. Miyamoto B, Yeh S, Wilding G and Chang C (1997) Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU 145 cells. Proc Nalt Acad Sci USA 95: 7379-7384
28. Nakhla AM, Romas NA and Rosner W (1997) Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. J Biol Chem 272: 6838-6841
29. Nazareth LV and Weigel NL (1996) Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271: 19900-19907
30. Romijn JC, Verkoelen CF and Schroeder FH (1988) Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug induced cytostatic and cytotoxic effects. Prostate 12: 99-110
31. Scher HI and Kolvenbag GJ (1997) The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur Urol 31: 3-7
32. Schuurmans ALG, Bolt J, Voorhorst M, Blankenstein RA and Mulder E (1988) Regulation of growth and epidermal growth factor receptor levels of LNCaP prostatic tumor cells by different steroids. Int J Cancer 42: 917-922
33. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274-281
34. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN and Balk SP (1995) Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. New Engl J Med 332: 1393-1398
35. Thomson AA, Foster BA and Cunha GR (1997) Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development 124: 2431-2439
36. Tilley WD, Wilson CM, Marcelli M and McPhaul MJ (1990) Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50: 5382-5386
37. Umekita Y, Hiipakka RA, Kokontis JM and Liao S (1996) Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93: 15152-15157
38. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CCJ, Mulller E, Boersma W and Trapman J (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189-193
39. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J and Brinkmann AO (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells effects steroid binding characteristics and response to anti-androgens. Biocehm Biophys Res Commun 17: 534-540
40. Veklscholte J, Berrevoets CA, Zegers ND, van der Kwast TH, Grootgoed JA and Mulder E (1992) Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 31: 7422-7430
41. Visakori T, Hyytinen F, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J and Kallionierni OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Gen 9: 401-406
42. Voegel JJ, Heine MJ, Zechel T, Chambon P and Gronemeyer H (1996) TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15: 3667-3675
43. Wilding G, Chen M and Gelmann FP (1989) Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14: 103-115
44. Yeh S and Chang C (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate. Proc Natl Acad Sci USA 93: 5517-5521